Here, we found that expression of VE-cadherin is not only downregulated by CSF from patients with MS, but that it is also modulated by the EBI2/oxysterol system, possibly opening up new ways to modulate the brain vasculature also in MS. Here, GPR183 is linked to myeloid sarcoma.